1. Scrip
  2. >>Business

AstraZeneca Hands LEO Dermatology Potential

 
• By Lubna Ahmed

AstraZeneca PLC is handing over two pipeline skin disease medicines, tralokinumab and brodalumab, to LEO Pharma for an upfront payment of $115m while it focuses on other key therapy areas. The UK big pharma has also put an end to its license with Valeant Pharmaceuticals for brodalumab in Europe in favor of its new partner.

AstraZeneca PLC has struck a strategic partnership with Leo Pharma AS in which the Danish company will acquire the global licence to tralokinumab, an anti-IL-13 monoclonal antibody for atopic dermatitis. AstraZeneca has also terminated the license for Valeant Pharmaceuticals International Inc.’s right to develop and commercialize IL-17 receptor monoclonal antibody brodalumab in Europe. Under this new agreement, dermatology focused LEO Pharma has been given the exclusive licence to brodalumab for patients with moderate-to-severe plaque psoriasis in Europe. (Also see "AstraZeneca Unburdens Itself Of Brodalumab" - Scrip, 1 September, 2015.)

LEO will make an upfront payment to AstraZeneca of $115m for the rights to tralokinumab in dermatitis and any future derma indications. It will also pay up to $1bn in commercial milestones, the details of which have not been disclosed, and royalties on product sales

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

More from Scrip

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.